Public-domain · open source
OpenJurist
← 570 U.S. 136 - F.T.C. v. Actavis, Inc.

F.T.C. v. Actavis, Inc.’s Empirical Analysis

570 U.S. 136 · 2013

Citation profile

38
cited by 38 later decisions
2
states following
March 2025
most recently cited

9 federal appellate · 5 district · 2 state decisions

How this case has been cited

Cited by 38 later decisions — most recently March 2025 · most notably National Wildlife Federation v. Environmental Protection Agency (2002), United Food & Commercial Workers Unions v. Warner Chilcott Ltd. (In re Asacol Antitrust Litig.) (2018)

9 federal appellate · 5 district · 2 state decisions

21020132020decided

Later decisions citing this case, by decade. The current decade is in progress, and our corpus holds fewer opinions from the most recent years, so the latest bars are undercounted — not a real decline.

Appellate journey

reviewedthe decision below (from Eleventh Circuit Court of Appeals)

Relationships

Applies 15 U.S.C. § 1 (§ 1 of the Sherman Antitrust Act) · 15 U.S.C. § 15 (§ 4 of the Clayton Antitrust Act of 1914) · 15 U.S.C. § 45 (§ 5 of the Federal Trade Commission Act of 1914) · 21 U.S.C. § 355 (Federal Food, Drug, and Cosmetic Act) · 35 U.S.C. § 271

Relies on Bell Atlantic Corp. v. Twombly · United States v. United States Gypsum Co. · Walker Process Equipment, Inc. v. Food MacHinery & Chemical Corp. · Professional Real Estate Investors, Inc. v. Columbia Pictures Industries, Inc. · Cybor Corporation v. Fas Technologies, Inc., and Fastar Ltd., Defendants-Cross

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 38 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

  1. “The Hatch-Waxman process, by allowing the generic to piggy-back on the pioneer's approval efforts, speeds the introduction of low-cost generic drugs to market, thereby furthering drug competition.”
    1 later decision quote this exact passage · from the majority
  2. “the basic reason is a desire to maintain and to share patent-generated monopoly profits,”
    1 later decision quote this exact passage · from the concurrence
  3. “pay the alleged infringer, rather than the other way around.”
    1 later decision quote this exact passage · from the majority

How this case has been treated — in progress

Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.